IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of “Moderate Buy” by Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have been assigned an average rating of “Moderate Buy” from the sixteen brokerages that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $53.67.

Several equities research analysts recently commented on the company. Oppenheimer restated an “outperform” rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Leerink Partnrs lowered IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Stephens assumed coverage on IDEAYA Biosciences in a research report on Monday, November 18th. They set an “overweight” rating and a $51.00 target price on the stock. Leerink Partners lowered IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and cut their target price for the company from $41.00 to $27.00 in a research report on Tuesday, November 5th. Finally, UBS Group assumed coverage on IDEAYA Biosciences in a research report on Thursday, October 24th. They set a “buy” rating and a $50.00 target price on the stock.

IDEAYA Biosciences Trading Down 2.3 %

NASDAQ IDYA opened at $22.72 on Friday. The business’s 50-day moving average price is $26.47 and its two-hundred day moving average price is $32.41. IDEAYA Biosciences has a 12 month low of $22.17 and a 12 month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same period in the prior year, the business posted ($0.46) EPS. As a group, sell-side analysts anticipate that IDEAYA Biosciences will post -2.45 earnings per share for the current year.

Institutional Trading of IDEAYA Biosciences

Several institutional investors and hedge funds have recently modified their holdings of IDYA. FMR LLC raised its stake in shares of IDEAYA Biosciences by 12.1% in the third quarter. FMR LLC now owns 12,635,653 shares of the company’s stock worth $400,297,000 after purchasing an additional 1,365,570 shares during the last quarter. RA Capital Management L.P. purchased a new stake in shares of IDEAYA Biosciences in the third quarter worth approximately $42,681,000. Janus Henderson Group PLC raised its stake in shares of IDEAYA Biosciences by 26.7% in the third quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock worth $163,518,000 after purchasing an additional 1,086,356 shares during the last quarter. Jennison Associates LLC raised its stake in shares of IDEAYA Biosciences by 136.6% in the third quarter. Jennison Associates LLC now owns 972,266 shares of the company’s stock worth $30,801,000 after purchasing an additional 561,404 shares during the last quarter. Finally, State Street Corp raised its stake in shares of IDEAYA Biosciences by 15.4% in the third quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after purchasing an additional 443,640 shares during the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.